Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.60 |
| ▸ | MGLL | Q99685 | 1/20 | 0.60 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.50 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.50 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.50 |
| ▸ | CCR5 | P51681 | 1/20 | 0.49 |
| ▸ | HTR1F | P30939 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4195672 | 0.90 | MGLL (0.57) | HSD11B1MGLLSLC18A3MEN1KMT2A | |
| SCHEMBL13944389 | 0.84 | SRD5A2 (0.57) | HSD11B1MGLLMEN1KMT2APOLB | |
| SCHEMBL28203216 | 0.84 | KMT2A (0.71) | HSD11B1MGLLMEN1KMT2AALDH1A1 | |
| SCHEMBL4192633 | 0.83 | HSD11B1 (0.65) | HSD11B1MGLLSLC18A3MEN1KMT2A | |
| SCHEMBL13463 | 0.83 | MGLL (0.58) | HSD11B1MGLLSLC18A3MEN1KMT2A | |
| SCHEMBL3391936 | 0.83 | HSD11B1 (0.69) | HSD11B1MGLLPOLBHTR1F | |
| SCHEMBL3391998 | 0.83 | MGLL (0.69) | HSD11B1MGLLMEN1KMT2A | |
| SCHEMBL13899388 | 0.83 | MGLL (0.60) | HSD11B1MGLLSLC18A3MEN1KMT2A | |
| SCHEMBL8081266 | 0.83 | MGLL (0.60) | HSD11B1MGLLSLC18A3MEN1KMT2A | |
| SCHEMBL2552838 | 0.82 | HTR2A (0.62) | HSD11B1MGLLSLC18A3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541572-B2 | Compounds for the treatment of inflammatory disorders | MERCK SHARP & DOHME CORP. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541572-B2 | Compounds for the treatment of inflammatory disorders | MERCK SHARP & DOHME CORP. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120010181-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | MERCK SHARP & DOHME CORP. | 2012-01-12 | — | — | US | disclosed |
| US-20120010181-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | MERCK SHARP & DOHME CORP. | 2012-01-12 | — | — | US | disclosed |
| EP-0013612-B1 | (PIPERIDINYLALKYL)QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-11-09 | — | — | EP | disclosed |
| US-4342870-A | SEROTONIN ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1982-08-03 | — | — | US | disclosed |
| EP-0037265-A1 | 3-(1-piperidinylalkyl)-4H-pyrido(1,2-a)pyrimidin-4-one derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1981-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010181-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, ADAMTS1, ADAMTS7 | HSD11B1 149/4885MGLL 1762/4885SLC18A3 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.